HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibacterial Soaps Reduce Risk Of Foodborne Illness – Industry Study

This article was originally published in The Rose Sheet

Executive Summary

A study funded in part by the Personal Care Products Council found use of antibacterial treatments to reduce concentrations of Shigella bacteria on participants’ hands significantly, leading to reduced levels transferred to melon balls and compelling estimates of reduced illness in eaters. FDA has requested such data as it considers GRASE conditions for antibacterial washes under a proposed rule issued in December 2013 that could require manufacturers to reformulate and relabel products.


Related Content

Industry Groups Seek Meeting With FDA On Antibacterial Ingredient Studies
Industry Cost Estimates For Proposed Antibacterials Rule Dwarf FDA’s
Minnesota First State To Ban Triclosan In Personal Cleansing Products
UMich Study Links Triclosan To Bacterial Colonization, Infection Risks
Antibac Soap Decline Likely In Reaction To Triclosan Debate
FDA Says Antiseptics Need Testing Or Face Reformulation, Relabeling



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts